Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Schott Full Year Revenues Up 7% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Schott Full Year Revenues Up 7%

55% of revenue in FY 2024 came from strong-margin HVS.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Schott Pharma
4Q Revenues: $249 million (+4%)
FY Revenues: $1 billion (+7%)
Comments: The main driver of SCHOTT Pharma’s revenue growth in Q4 2024 was the strong year-end finish of the DDS segment. Revenues in the DDS segment reached $124 million, an increase of 12% yoy (at constant currencies: 11%). Q4 represented the highest quarterly revenue in this segment. This development was driven by the ongoing strong demand for prefillable syringes and, in particular, by good momentum in glass syringes. On a twelve-month basis, revenue in the DDS segment amounted to $461.3 million, an increase of 28% yoy (at constant currencies: 26%). Based on the good development in the DDS segment, which consists only of HVS products, the HVS revenue share increased by seven percentage points to 55%.
 
Meanwhile, in FY 2024, SCHOTT Pharma achieved strong revenue growth of 7% (at constant currencies: 12%). This growth was primarily fueled by the high demand for HVS products and SCHOTT Pharma’s continuous expansion of the corresponding capacities. 55% of revenue in FY 2024 came from strong-margin HVS, bringing the company closer to its mid-term target of above 60%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters